With Matt Stafford now on the trading block, the Chicago Bears, Indianapolis Colts, Denver Broncos and San Francisco 49ers are among the many teams expected to make a play for the Detroit Lions quarterback.
With Matt Stafford now on the trading block, the Chicago Bears, Indianapolis Colts, Denver Broncos and San Francisco 49ers are among the many teams expected to make a play for the Detroit Lions quarterback.
BERLIN — A German man has been charged with espionage for allegedly passing information on properties used by the German parliament to Russian military intelligence, prosecutors said Thursday. The suspect, identified only as Jens F. in line with German privacy rules, worked for a company that had been repeatedly contracted to check portable electrical appliances by the Bundestag, or the lower house of parliament, federal prosecutors said in a statement. As a result of that, he had access to PDF files with floor plans of the properties involved. The Bundestag is based in the Reichstag building, a Berlin landmark, but also uses several other sites. Prosecutors said, at some point before early September 2017, the suspect “decided of his own accord” to give information on the properties to Russian intelligence. They said he sent the PDF files to an employee of the Russian Embassy in Berlin who was an officer with Russia's GRU military intelligence agency. They didn't specify how his activities came to light. The charges against the suspect, who is not in custody, were filed at a Berlin court on Feb. 12. The court will have to decide whether to go ahead with a trial. Relations between Germany and Russia have been buffeted by a growing list of issues in recent years. In October, the European Union imposed sanctions on two Russian officials and part of the GRU agency over a cyberattack against the German parliament in 2015. In addition, a Russian man accused of killing a Georgian man in broad daylight in downtown Berlin on Moscow’s orders in 2019 is on trial in Berlin. And last year's poisoning of Russian opposition leader Alexei Navalny, who was flown to Germany for treatment and then arrested immediately after he returned to Russia, has added another layer of tensions. The Associated Press
CHICAGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- TransUnion (NYSE: TRU) today announced that its Board of Directors declared a cash dividend of $0.075 per share for the fourth quarter 2020. The dividend will be payable on March 26, 2021, to shareholders of record on March 11, 2021. About TransUnion (NYSE: TRU)TransUnion is a global information and insights company that makes trust possible in the modern economy. We do this by providing a comprehensive picture of each person so they can be reliably and safely represented in the marketplace. As a result, businesses and consumers can transact with confidence and achieve great things. We call this Information for Good.® A leading presence in more than 30 countries across five continents, TransUnion provides solutions that help create economic opportunity, great experiences and personal empowerment for hundreds of millions of people. http://www.transunion.com/business Efirstname.lastname@example.orgTelephone312-985-2860
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We are pleased with the substantial progress the Company made in 2020, particularly in light of the significant challenges resulting from the COVID-19 pandemic,” stated Paul Friedman, M.D., Chief Executive Officer of Madrigal. “We completed enrollment in the Company’s Phase 3 MAESTRO-NAFLD-1 trial in less than 12 months, and we also made significant progress in enrollment of our Phase 3 MAESTRO-NASH trial.” Dr. Friedman continued, “We advanced the development of Madrigal’s commercial capabilities in 2020, with Remy Sukhija joining the Company as Senior Vice President and Chief Commercial Officer. Remy and his team have embarked on detailed analyses of the market opportunity for resmetirom as we continue to execute our Phase 3 clinical programs.” Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, “Because of enthusiasm from patients and investigators who wanted to participate in the study, we expanded enrollment in MAESTRO-NAFLD-1 to more than 1,200 patients, which provides a robust safety database and provides further opportunity to study selected patient subgroups. We completed enrollment in the blinded arms of the trial in October, and we presented 16-week data from the open label arm of the trial in November 2020, at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting.” Dr. Taub continued, “We expect to achieve several important clinical milestones in 2021, including completion of enrollment in the 52-week, serial liver biopsy population for Subpart H approval of MAESTRO-NASH, which we expect to complete in the second quarter; presentation of data from the open label arm of MAESTRO-NAFLD-1 at a major medical conference; and release of topline data from the blinded arms of MAESTRO-NAFLD-1 by the end of the year.” Financial Results for the Three and Twelve Months Ended December 31, 2020As of December 31, 2020, Madrigal had cash, cash equivalents and marketable securities of $284.1 million, compared to $439.0 million at December 31, 2019. The decrease in cash and marketable securities resulted primarily from cash used in operations of $157.6 million. Operating expenses were $59.6 million and $206.7 million for the three and twelve month periods ended December 31, 2020, compared to $30.0 million and $95.0 million in the comparable prior year periods. Research and development expenses for the three and twelve month periods ended December 31, 2020 were $53.4 million and $184.8 million, compared to $24.9 million and $72.3 million in the comparable prior year periods. The increases are primarily attributable to additional activities related to the Phase 3 clinical trials initiated in 2019, an increase in manufacturing costs to support ongoing clinical trials and to prepare for commercialization, and an increase in head count and related expenses. General and administrative expenses for the three and twelve month periods ended December 31, 2020 were $6.1 million and $21.9 million, compared to $5.0 million and $22.6 million in the comparable prior year periods. The increase in general and administrative expenses for the latest three month period is due primarily to increases in head count and consulting costs. The decrease in general and administrative expenses for the latest twelve month period was due primarily to a decrease in non-cash stock compensation from stock option awards, which was partially offset by increases in other general and administrative expenses. Interest income for the three and twelve month periods ended December 31, 2020 was $0.4 million and $4.3 million, compared to $2.2 million and $11.0 million in the comparable prior year periods. The decreases in interest income for the latest three and twelve month periods were due primarily to lower average principal balances in our investment accounts in 2020, and decreased interest rates. About Resmetirom (MGL-3196) Thyroid hormone, through activation of its β-receptor in hepatocytes, plays a central role in liver function impacting a range of health parameters from levels of serum cholesterol and triglycerides to the pathological buildup of fat in the liver. Thyroid hormone receptor (THR)-β action in the liver is key to proper function of the liver, including regulation of mitochondrial activity such as breakdown of liver fat and control of the level of normal, healthy mitochondria. Patients with NASH have reduced levels of thyroid hormone activity in the liver with resultant impaired hepatic function, in part due to the inflamed state of the liver that causes degradation of thyroid hormone. To exploit the thyroid hormone receptor (THR)-β pathway for therapeutic purposes in cardio-metabolic and liver diseases, it is important to avoid activity at the THR-α receptor, the predominant systemic receptor for thyroid hormone that is responsible for activity outside the liver including in heart and bone. The lack of selectivity of older thyromimetic compounds, chemically-related toxicities and undesirable distribution in the body led to safety concerns. Madrigal recognized that greater selectivity for thyroid hormone receptor (THR)-β and liver targeting might overcome these challenges and deliver the full therapeutic potential of THR-β agonism. Resmetirom has been shown to be highly selective based on 1) THR-β receptor functional selectivity based on both in vitro and in vivo assays and 2) specific uptake into the liver, its site of action, virtually avoiding any uptake into tissues outside the liver. In short and long term human and animal studies, resmetirom has been confirmed to be safe and devoid of activity at the THR-α receptor and without impact on bone or cardiac parameters. Resmetirom does not impact the thyroid axis hormones, including the central thyroid axis. Madrigal believes that resmetirom is the first orally administered, small-molecule, liver-directed, truly β-selective THR agonist. About the Phase 3 Registration Program for the Treatment of NASH (Non-alcoholic steatohepatitis)Analyses from the resmetirom Phase 2 NASH study demonstrate that the magnitude of liver fat reduction accurately predicts NASH resolution and liver fibrosis reduction and, specifically, that the resmetirom doses being used in Madrigal’s Phase 3 MAESTRO-NASH trial could achieve the level of fat reduction predictive of NASH resolution and fibrosis reduction [Madrigal COVID and ABSTRACT Press Release_20200414]. The Phase 3 MAESTRO-NASH trial is expected to enroll 900 patients with biopsy-proven NASH (fibrosis stage 2 or 3), randomized 1:1:1 to receive resmetirom 80 mg once a day, 100 mg once a day, or placebo. After 52 weeks of treatment a second biopsy is performed. The primary surrogate endpoint on biopsy will be NASH resolution, with at least a 2-point reduction in NAS (NASH Activity Score), and with no worsening of fibrosis. Two key secondary endpoints are liver fibrosis improvement of at least one stage, with no worsening of NASH, and lowering of LDL-cholesterol [ClinicalTrials.gov/NCT03900429]. A second 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom, MAESTRO-NAFLD-1, was initiated in December 2019 in 700 patients with non-alcoholic fatty liver disease (NAFLD), presumed NASH, randomized 1:1:1 to receive resmetirom 80 mg once a day, 100 mg once a day, or placebo. MAESTRO-NAFLD-1 also includes a 100 mg resmetirom open label arm in up to 100 patients. The trial was expanded to include more than 1,200 patients, in order to significantly enhance resmetirom’s safety database and provide further opportunity to study selected patient subgroups. Unlike MAESTRO-NASH, MAESTRO-NAFLD-1 is a non-biopsy study and represents a “real-life” NASH study. NASH or presumed NASH is documented using historical liver biopsy or non-invasive techniques including fibroscan and MRI-PDFF. Using non-invasive measures, MAESTRO-NAFLD-1 is designed to provide incremental safety information to support the NASH indication as well as provide additional data regarding clinically relevant key secondary efficacy endpoints to better characterize the potential clinical benefits of resmetirom on cardiovascular and liver related endpoints. These key secondary endpoints include LDL-cholesterol, apolipoprotein B and triglyceride (TG) lowering; reduction of liver fat as determined by magnetic resonance imaging, proton density fat fraction (MRI-PDFF); and reduction of PRO-C3, a NASH fibrosis biomarker. [ClinicalTrials.gov/NCT04197479] Additional secondary and exploratory endpoints will be assessed including reduction in liver enzymes, fibroscan scores and other fibrosis and inflammatory biomarkers.These and other data, including safety parameters, form the basis for potential subpart H submission to FDA for accelerated approval for the treatment of NASH. The original 900 patients in the MAESTRO-NASH study will continue on therapy after the initial 52-week treatment period; up to another 1,100 patients are to be added using the same randomization plan and the study is expected to continue for up to 54 months to accrue and measure clinical events, most relevantly progression to cirrhosis. About Resmetirom’s Potential to Confer Cardiovascular Risk Reduction in NASH patientsAdditionally, resmetirom lowers multiple atherogenic lipids, including LDL cholesterol, apolipoprotein B, triglycerides, and lipoprotein (a), as demonstrated in Phase 2, a key differentiating factor compared with other NASH therapeutics. The magnitude of reduction of these lipids support a potential indication for treatment of hyperlipidemia in NASH patients and predicts a potential for benefit on cardiovascular (CV) events in NASH patients who die most frequently of CV, not liver disease. Because of their diabetes, dyslipidemia, hypertension, obesity in concert with an inflamed, fatty liver, NASH patients, particularly those with advanced fibrosis, are at a substantially increased CV risk compared to the general population. Resmetirom’s ability to decrease liver fat, which is an independent risk factor for CV events, and resmetirom’s effect to reduce atherogenic lipids are being further evaluated in several key secondary endpoints in both MAESTRO Phase 3 clinical studies. About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAGLD-1, designed to demonstrate multiple benefits across a broad spectrum of NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) patients. For more information, visit www.madrigalpharma.com. Forward-Looking Statements This communication contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on our beliefs and assumptions and on information currently available to us, but are subject to factors beyond our control. Forward-looking statements include but are not limited to statements or references concerning: our clinical trials; research and development activities; the timing and results associated with the future development of our lead product candidate, MGL-3196 (resmetirom); the timing and completion of projected 2021 clinical milestone events; our primary and secondary study endpoints for resmetirom and the potential for achieving such endpoints and projections; optimal dosing levels for resmetirom; projections regarding potential future NASH resolution, safety, fibrosis treatment, cardiovascular effects, lipid treatment or biomarker effects with resmetirom; the predictive power of liver fat reduction on NASH resolution with fibrosis reduction or improvement; the achievement of enrollment objectives concerning patient number, safety database and/or timing for our studies; potential NASH or NAFLD patient risk profile benefits with resmetirom; and our possible or assumed future results of operations and expenses, business strategies and plans, capital needs and financing plans, trends, market sizing, competitive position, industry environment and potential growth opportunities, among other things. Forward-looking statements: reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events; include all statements that are not historical facts; and can be identified by terms such as “allow,” “anticipates,” “be,” “believes,” “continue,” “could,” “demonstrates,” ”design,” “estimates,” “expects,” “forecasts,” “future,” “goal,” “hopeful,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” ”predictive,” “projects,” “seeks,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Although management presently believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: our clinical development of resmetirom; enrollment uncertainties, generally and in relation to COVID-19 shelter-in-place and social distancing measures and individual precautionary measures that may be implemented or continued for an uncertain period of time; outcomes or trends from competitive studies; future topline data timing or results; the risks of achieving potential benefits in studies that include substantially more patients than our prior studies; the timing and outcomes of clinical studies of resmetirom; and the uncertainties inherent in clinical testing. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal's filings with the U.S. Securities and Exchange Commission for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. We specifically discuss these risks and uncertainties in greater detail in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020, as well as in our other filings with the SEC. Investor Contact: Marc Schneebaum, Madrigal Pharmaceuticals, Inc. IR@madrigalpharma.com Media Contact: Mike Beyer, Sam Brown Inc. email@example.com 312 961 2502 (Tables Follow) Madrigal Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited) Three Months Ended Twelve Months Ended December 31, December 31, 2020 2019 2020 2019 Revenues: Total revenues$- $- $- $- Operating expenses: Research and development 53,429 24,910 184,809 72,324 General and administrative 6,126 5,044 21,864 22,648 Total operating expenses 59,555 29,954 206,673 94,972 Loss from operations (59,555) (29,954) (206,673) (94,972) Interest income, net 432 2,214 4,329 11,024 Other income - - 100 - Net loss$(59,123)$(27,740) $(202,244)$(83,948) Basic and diluted net loss per common share$(3.82)$(1.80) $(13.09)$(5.45) Basic and diluted weighted average number of common shares outstanding 15,475,291 15,429,154 15,446,638 15,394,659 Madrigal Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (in thousands) (unaudited) December 31,December 31, 2020 2019 Assets Cash, cash equivalents and marketable securities$284,149 $439,045 Other current assets 1,014 1,152 Other non-current assets 1,832 1,859 Total assets$286,995 $442,056 Liabilities and Equity Current liabilities$46,557 $25,130 Long-term liabilities 468 361 Stockholders’ equity 239,970 416,565 Total liabilities and stockholders’ equity$286,995 $442,056
The Court of Appeal heard arguments in the prominent Aljunied Hougang Town Council (AHTC) case on Thursday (25 February) before a five-judge bench.
The African Union is backing calls for drugmakers to waive some intellectual property rights on COVID-19 medicines and vaccines to speed up their rollout to poor countries, the head of its disease control body said on Thursday. South Africa and India, which both manufacture drugs and vaccines, made the proposal at the World Trade Organization (WTO) last year, arguing that intellectual property (IP) rules were hindering the urgent scale-up of vaccine production and provision of medical products to some patients.
Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus. They are also in talks with regulatory authorities about testing a vaccine modified to protect specifically against the highly transmissible new variant found in South Africa and elsewhere, known as B.1.351, as a second arm of the same study. The companies believe their current two-dose vaccine will work against the South African variant as well as one found in the United Kingdom and elsewhere.
Wipro recognized as one of World’s Most Ethical Companies for the tenth consecutive year.
The "Dairy Enzymes Market Share, Size, Trends, Industry Analysis Report, By Product Class; By Source; By Application; By Regions - Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
An expected dash by big corporations for offsets to meet their climate targets has prompted financial exchanges to launch carbon futures contracts to capitalise on what could be a multi-billion dollar market. Carbon offsets, generated by emissions reduction projects, such as tree planting or shifts to less polluting fuels, have struggled for years to gain credibility, but as climate action has become urgent, their market is expected to grow to as much as $50 billion by 2030. Among the major corporations that say they expect to use them to compensate for any emissions they cannot cut from their operations and products are Unilever, EasyJet, Royal Dutch Shell and BP, which all have climate targets.
Trees for Tom is a collaboration between two leading environmental charities chosen by the Second World War veteran’s family.
Dublin, Feb. 25, 2021 (GLOBE NEWSWIRE) -- The "Global Acrylonitrile Butadiene Styrene (ABS) Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. The publisher has been monitoring the acrylonitrile butadiene styrene (ABS) market and it is poised to grow by 1387.12 million t during 2021-2025, progressing at a CAGR of 3% during the forecast period. The reports on acrylonitrile butadiene styrene (ABS) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing demand for ABS from China, rising demand for ABS from the automotive sector, and rise in demand for plastic pipes and sheets. The acrylonitrile butadiene styrene (ABS) market analysis includes application segment and geographical landscapes. This study identifies rise in demand for plastic pipes and sheets as one of the prime reasons driving the acrylonitrile butadiene styrene (ABS) market growth during the next few years. The rise in demand for plastic pipes and sheets will lead to sizable demand in the market.The acrylonitrile butadiene styrene (ABS) market covers the following areas: Acrylonitrile butadiene styrene (ABS) market sizingAcrylonitrile butadiene styrene (ABS) market forecastAcrylonitrile butadiene styrene (ABS) market industry analysis The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading acrylonitrile butadiene styrene (ABS) market vendors that include Avient Corp., BASF SE, Chi Mei Corp., Daicel Corp., Formosa Plastics Corp., INEOS Group Holdings SA, LG Chem Ltd., Mitsui Chemicals, Inc., Saudi Basic Industries Corp., and Toray Industries Inc. Also, the acrylonitrile butadiene styrene (ABS) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.Key Topics Covered: 1. Executive Summary Market Overview 2. Market Landscape Market ecosystemMarket characteristicsValue chain analysis 3. Market Sizing Market definitionMarket segment analysisMarket size 2020Market outlook: Forecast for 2020 - 2025 4. Five Forces Analysis Five forces summaryBargaining power of buyersBargaining power of suppliersThreat of new entrantsThreat of substitutesThreat of rivalryMarket condition 5. Market Segmentation by Application Market segmentsComparison by ApplicationAppliances - Market size and forecast 2020-2025Electrical and electronics - Market size and forecast 2020-2025Automotive - Market size and forecast 2020-2025Construction - Market size and forecast 2020-2025Others - Market size and forecast 2020-2025Market opportunity by Application 6. Customer landscape7. Geographic Landscape Geographic segmentationGeographic comparisonAPAC - Market size and forecast 2020-2025Europe - Market size and forecast 2020-2025North America - Market size and forecast 2020-2025MEA - Market size and forecast 2020-2025South America - Market size and forecast 2020-2025Key leading countriesMarket opportunity by geographyMarket driversMarket challengesMarket trends 8. Vendor Landscape Competitive scenarioVendor landscapeLandscape disruptionIndustry risks 9. Vendor Analysis Vendors coveredMarket positioning of vendorsAvient Corp.BASF SEChi Mei Corp.Daicel Corp.Formosa Plastics Corp.INEOS Group Holdings SALG Chem Ltd.Saudi Basic Industries Corp.Toray Industries Inc. 10. Appendix Scope of the reportCurrency conversion rates for US$Research methodologyList of abbreviations For more information about this report visit https://www.researchandmarkets.com/r/jooq3t CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Australia’s parliament on Thursday passed the last elements of the controversial new law that will require major tech firms to pay local publishers for news. Amendments earlier this week brought to an end a standoff between the Australian government and Facebook, which last week took the dramatic move of disabling Australian users’ ability to share […]
Daimler Trucks' shift to zero-emission vehicles will lead to thousands of job losses at the company's German powertrain plants by 2033, its chairman said on Thursday, adding cuts would be gradual and achieved via retirements and voluntary packages. "This is no revolution coming over night, this is an evolution," Martin Daum told journalists on a conference call. Electric vehicles have far fewer moving parts than traditional combustion engine models and as automakers shift production their engine and powertrain plants are expected to employ far fewer people over time.
The Logistics industry in the UAE is one of the top 5 logistics markets in the world, given the favourable location of UAE at the intersection of Asia, Africa & Europe.Gurugram, India, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Etihad Cargo has outlined its plans to focus on COVID-19 focused services, setting up a dedicated COVID-19 distribution team in anticipation of a vaccine for the virus. Its new specialized pharma and healthcare product PharmaLife, will focus on key gateways including Abu Dhabi, Barcelona, Chicago, Paris, Dubai, Frankfurt, Hyderabad, London, Milan, Melbourne, Mumbai, Shanghai, Singapore, and Sydney.Amazon.ae announced that it has launched International Shopping Experience, delivering items from the UAE to Bahrain, Kuwait and Oman. The delivery includes import fees along with customs clearance managed by Amazon’s couriers. The move acts as a strong fillip to the growth of e-commerce across the Middle Eastern region. In a historic step for global trade, the UAE and Israel agreed to normalize relations in mid-August 2020 and signed a normalization agreement in September. In October, a ship carrying cargo from the UAE, docked at an Israel’s Haifa Port. The ship will bring cargo from the UAE to Israel on a weekly basis. Impact of COVID-19: The COVID-19 pandemic impacted overall supply chain operations in the UAE, with road freight due to sealing of borders and air freight due to flight cancellation being the major sufferers. Moreover, companies have been struggling with employee infections and have been forced to move to a remote working setup, at least for the non-operational staff. The industry is gradually recovering from the transport restrictions. Going forward, pharmaceutical logistics will play an important part in distribution of the COVID-19 vaccine, once it is ready and is hence expected to lead vertical market growth in the future. The demand for essentials and daily usage consumer products went up during the lockdown period, and is expected to continue to grow, as the retail segment looks to be the highest contributing vertical to logistics in the UAE. Freight Forwarding is expected to be Lead Contributor: While the UAE Logistics industry is composed of different service segments such as Freight Forwarding, Warehousing, Express Delivery and Value Added Services, it is the Freight Forwarding Segment that is expected to continue being the leading segment in the future. Express market segment is identified to grow at the fastest pace, due to growth in e-commerce deliveries and companies. Technological Advancement to Drive Growth: Government Initiatives such as Dubai IoT Strategy, Dubai Block Chain Strategy, Introductions of drones for last-mile delivery, UAE National AI Program, Smart Dubai 2021, Dubai 3D printing Strategy, Dubai Data Initiatives and National Innovation Strategy will revolutionize the logistics and warehousing market of UAE. Analysts at Ken Research in their latest publication "Competition Benchmarking of Top Logistics Players in UAE in Transportation, Warehousing, 3PL, International Express, Domestic Express, Automotive, Pharma, Oil and Gas and Retail Logistics" observe that the UAE Logistics Market is expected to grow at a decent pace, backed by upcoming new businesses in the country along with the favorable position of the country as a logistics and trans-shipment hub globally. The Logistics Market in UAE is expected to grow at a CAGR of 3.9% from 2019 to 2025, in terms of revenues. The rescheduled Expo 2020 would also play a part in growth of the industry during the early period. Key Target Audience:-3PL Logistics CompaniesIntegrated Logistics CompaniesE-Commerce CompaniesOil & Gas CompaniesRetail CompaniesPharmaceutical CompaniesLogistics/Supply Chain Industry Associations Time Period Captured in the Report:-Historical: 2015 to 2019Future: 2019 to 2025 Companies Mentioned:-Kuehne + NagelAgilityEmirates PostAl-Futtaim LogisticsDB SchenkerDHLFedEx ExpressUPSAllied TransportFreightworksZajel Courier ServicesTime ExpressBollore LogisticsDanzas AEIMohebi LogisticsHellmann Worldwide LogisticsTristarGulf Agency CompanyCEVA LogisticsATSSkynetSky ExpressAvalon General Land TransportGSL (Global Shipping and Logistics)RSA GlobalRoadlink TransportAl Mujarad Transport Key Topics Covered in the Report:-UAE Logistics Industry OverviewUAE Logistics Industry Market Size by Sub-Service, 2015-2025UAE Logistics Industry Market Size by Vertical, 2015-2025UAE Logistics Sub-Service Market Segmentation by End User Verticals, 2019-2025UAE Warehousing Market Segmentation by Type of Warehouses, 2019Competitive Landscape including Major Players in each Service Segment, 2019Competitive Landscape including Major Players in each Vertical Segment, 2019Cross-Comparison of Major Freight Forwarding and Express Players, 2019Company Profiles of Major Players in each SegmentMajor Trade Lanes for Land Freight, Sea Freight, Air Freight and International Express, 2019Pricing Analysis for Major Players by Service Mix, 2019 For More Information on the research report, refer to below link:- Logistics industry in the UAE Related Reports:- Saudi Arabia Dry Logistics and Warehousing Market Outlook to 2025 – Warehousing Automation and Investment within Transport Infrastructure to Drive Market RevenueCompetition Benchmarking of Top Logistics Players in KSA in Transportation, Warehousing, 3PL, International Express, Domestic Express, Automotive, Pharma, Oil and Gas and Retail LogisticsSaudi Arabia Automotive & Spare Parts Logistics Market Outlook to 2025: Lifting of Ban on Female Drivers and Growing Aftermarket for Spare Parts to Influence Market GrowthSaudi Arabia Pharmaceutical Logistics Market Outlook to 2025: Rising Demand for Pharmaceutical Drugs and Government Support to Healthcare Will Drive Market Growth Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Ankur@kenresearch.com +91-9015378249 CONTACT: Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Ankur@kenresearch.com +91-9015378249
STORE Capital (NYSE: STOR) invests in single-tenant properties occupied by tenants in the service, retail, and manufacturing industries. You might be surprised to learn that STORE's addressable market of existing properties is several trillion dollars in size. In this Fool Live video clip, recorded on Feb. 16, Millionacres real estate analyst Matt Frankel, CFP, and editor Deidre Woollard discuss how STORE Capital has been doing recently and the enormous addressable market opportunity the company has.
Design news for February: tech to keep in touch and the world's biggest drawing club Swiss furniture, Japanese ceramics and the best bus station in Lithuania. From left: Spheres marquetry sideboard by Christine Meyer-Eaglestone at Collect Fair. Teapot by Hiroshi Kikuchi of Kasama Potters. No Isolation’s AV1 36. Jason Polan T shirt for Uniqlo Composite: PR
Shares in defence company BAE nudged higher in early trading after it delivered earnings per share ahead of market expectations.
YEREVAN, Armenia — Armenia's prime minister accused top military officers on Thursday of attempting a coup after they demanded he step down, adding fuel to monthslong protests calling for his resignation following the nation's defeat in a conflict with Azerbaijan over the Nagorno-Karabakh region. The demonstrations began immediately after Prime Minister Nikol Pashinyan signed a Nov. 10 peace deal that saw Azerbaijan reclaim control over large parts of Nagorno-Karabakh and surrounding areas that had been held by Armenian forces for more than a quarter-century. Those protests have gathered pace this week, and the feud with his top military commanders has weakened Pashinyan's position. The immediate trigger for the standoff was Pashinyan’s decision to oust the first deputy chief of the military's General Staff, a group of the armed forces' top commanders. In response, the General Staff called for Pashinyan's resignation — but the prime minister doubled down and dismissed the chief of the General Staff. He described the military's statement as a “military coup attempt” and urged troops to only listen to his orders. He also called on his backers to come to the streets and then later walked among them, using a loudspeaker to rally support. “We need a conversation, not a confrontation,” he said. Pashinyan denied rumours that he was preparing to flee the country. Supporters of Pashinyan and the opposition engaged in sporadic scuffles on the streets of Yerevan on Thursday. Russia's government voiced concern over the tensions but emphasized that Armenia needs to sort it out itself. “We are calling for calm and believe that the situation should remain in the constitutional filed,” Kremlin spokesman Dmitry Peskov told reporters. The crisis has its roots in Armenia's humiliating defeat in heavy fighting with Azerbaijan over Nagorno-Karabakh that erupted in late September and lasted 44 days. A Russian-brokered agreement ended the conflict in which the Azerbaijani army routed Armenian forces — but only after more than 6,000 people died on both sides. Pashinyan has defended the peace deal as a painful but necessary move to prevent Azerbaijan from overrunning the entire Nagorno-Karabakh region, which lies within Azerbaijan but was under the control of ethnic Armenian forces backed by Armenia since a separatist war there ended in 1994. Opposition groups have dismissed that argument. On Thursday, opposition demonstrators swarmed the streets of the Armenian capital, chanting “Nikol, you traitor!” and “Nikol, resign!” They paralyzed traffic all around Yerevan. Despite the simmering public anger over the military defeat, Pashinyan has manoeuvred to shore up his rule and the protests died down amid the winter's cold. But the opposition demonstrations resumed with new vigour this week — and then came the spat with top officers. Pashinyan fired the deputy chief of the General Staff, Lt. Gen. Tiran Khachatryan, earlier this week after he derided the prime minister's claim that just 10% of Russia-supplied Iskander missiles that Armenia used in the conflict exploded on impact. The General Staff responded Thursday with a statement demanding Pashinyan's resignation and warned the government against trying to use force against the opposition demonstrators. Immediately after the statement, Pashinyan dismissed the General Staff chief, Col. Gen. Onik Gasparyan. ____ Associated Press writers Vladimir Isachenkov and Daria Litvinova in Moscow contributed to this report. Avet Demourian, The Associated Press
Semenya hopes her latest bid will see the European court "put an end to the longstanding human rights violations by World Athletics against women athletes".
The British Gas owner reported a 31% drop in underlying operating profits to £447 million for 2020.